FindTrial
Sign In

Alternative donor hematopoietic stem cell transplantation as first line therapy for children with severe aplastic anemia

Alternative donor hematopoietic stem cell transplantation as first line therapy for children with severe aplastic anemia

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-ONC-14004526
Enrollment
Unknown
Registered
2014-03-07
Start date
2010-01-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

aplastic anemia

Interventions

Cliniacal observation group:alternative donor hematopoietic stem cell transplantation

Sponsors

Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
1 Years to 18 Years

Inclusion criteria

Inclusion criteria: 1. Severe aplastic anemia; 2. Aged younger than 18 years old; 3. With 9-10/10 HLA matched unrelated donor or 5/6 HLA matched related donor; 4. Life expectancy: more than one month; 5. Sign the informed consent document.

Exclusion criteria

Exclusion criteria: 1. Congenital bone marrow failure; 2. With HLA matched sibling donor; 3. Severe organ dysfunction: serum ALT >3 times ULN, Ccr<60ml/min, left ventricular ejection fraction<50%.

Design outcomes

Primary

MeasureTime frame
Overall Survival;Disease Free Survival;—

Countries

China

Contacts

Public ContactJing Chen

Shanghai Children's Medical Center affiliated to Shanghai Jiao Tong University School of Medicine

chenjingscmc@hotmail.com+86 21 38626161-82073

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026